BridgeMD
New treatment option for Mild Respiratory Distress
Official title A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress
ClinicalTrials.gov ID: NCT06658535
What this study is testing
What is dodecafluoropentane (0.025 mL/kg)?
dodecafluoropentane (0.025 mL/kg) is an investigational medicine, being studied as a potential treatment for mild respiratory distress.
Also referred to as NanO2™.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- EXTEND is a dose escalation study of NanO2™ in patients with mild respiratory distress who are at risk for mechanical ventilation. The study will establish dosing guidelines for a Phase 2 study.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Requiring supplemental oxygen but ≤ 6L oxygen by nasal cannula to maintain an oxygen saturation \>92% or PaO2 \>60mmHg
- Admitted to a hospital with symptoms of mild RD
- Signed informed consent obtained from the subject or subject's legally authorized representative
- Agrees to not participate in another clinical trial for the treatment of mild RD through Day 28
You likely can't join if
- Presence of extracorporeal membrane oxygenation
- Unstable hypertension
- History of significantly impaired renal function defined as an eGFR ≤ 30mL/min/1.73m2 (MDRD equation or similar) or impaired hepatic function defined...
- Presence of pulmonary embolism at baseline
- Evidence of right ventricular heart failure
- Unstable hemodynamically as defined by receiving 0.5μg/kg/min or greater norepinephrine
See the full eligibility criteria
- Requiring supplemental oxygen but ≤ 6L oxygen by nasal cannula to maintain an oxygen saturation \>92% or PaO2 \>60mmHg
- Admitted to a hospital with symptoms of mild RD
- Signed informed consent obtained from the subject or subject's legally authorized representative
- Agrees to not participate in another clinical trial for the treatment of mild RD through Day 28
- Presence of extracorporeal membrane oxygenation
- Unstable hypertension
- History of significantly impaired renal function defined as an eGFR ≤ 30mL/min/1.73m2 (MDRD equation or similar) or impaired hepatic function defined as the presence of decompensated cirrhosis (acute deterioration in...
- Presence of pulmonary embolism at baseline
- Evidence of right ventricular heart failure
- Unstable hemodynamically as defined by receiving 0.5μg/kg/min or greater norepinephrine
- Inability to comply with the study procedures
- Currently pregnant or breastfeeding
- Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 48 hours
- History or evidence of any other clinically significant condition that, in the opinion of the investigator, might pose a safety risk to people or interfere with study procedures, evaluation, or completion
The study team makes the final eligibility decision.
Where it's taking place
- Edmonton, Alberta, Canada
- Montreal, Quebec, Canada
Compensation & support
A stipend or compensation may be offered.
Compensation likely.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Edmonton, Alberta, Canada; Montreal, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.